Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

ABSTRACT:

Purpose

Morphologically heterogeneous prostate cancers that behave clinically like small-cell prostate cancers (SCPC) share their chemotherapy responsiveness. We asked whether these clinically defined, morphologically diverse, "aggressive variant prostate cancer (AVPC)" also share molecular features with SCPC.

Experimental design

Fifty-nine prostate cancer samples from 40 clinical trial participants meeting AVPC criteria, and 8 patient-tumor derived xenografts (PDX) from 6 of them, were stained for markers aberrantly expressed in SCPC. DNA from 36 and 8 PDX was analyzed by Oncoscan for copy number gains (CNG) and losses (CNL). We used the AVPC PDX to expand observations and referenced publicly available datasets to arrive at a candidate molecular signature for the AVPC.

R

SUBMITTER: Aparicio AM 

PROVIDER: S-EPMC4794379 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature